Non-small cell lung cancer (NSCLC) Clinical Trials in Lebanon, NH
As of August 2026, 11 paid clinical trials are recruiting for Non-small cell lung cancer (NSCLC) in Lebanon, New Hampshire. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Related specialties in Lebanon
Filter results
Newly added in Lebanon
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
12 clinical trials for Non-small cell lung cancer (NSCLC)
·Clear filters·A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Top Research Study Locations in Lebanon
Researchers run research studies in Lebanon, NH at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Acute Myeloid Leukemia, Anatomic Stage II Breast Cancer AJCC v8, B Acute Lymphoblastic Leukemia | 65 |
| Dartmouth-Hitchcock Medical Center | Neoplasm Metastasis, Trauma Injury, Cancer | 65 |
| Dartmouth Hitchcock Medical Center | Amyotrophic Lateral Sclerosis, Epilepsy, Anesthesia | 56 |
| Dartmouth Hitchcock | ALK Genomic Tumor Aberrations, Advanced Cancer, Advanced Solid Tumor | 9 |
| Dartmouth Cancer Center | Adjuvant Treatment, Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab | 5 |
| Dartmouth Health | Colorectal Adenoma, Colorectal Cancer, Colorectal Neoplasms | 5 |
| Dartmouth-Hitchcock Clinic | Breast Cancer, Fragility Fracture, Infant | 4 |
| Ascendis Investigational Site | Growth Hormone Deficiency | 2 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC), Non-Small Cell Lung Cancer | 2 |
| Dartmouth Hitchcock Medical Center | Carcinoma, Non-Small-Cell Lung | 2 |
| Dartmouth-Health | Spastic Hemiparesis, Spinal Fusion, Spinal Stenosis | 2 |
| Dartmouth-Health Lebanon | Cognitive Dysfunction, Memory Disorders, Memory Dysfunction | 2 |
| Dartmouth-Hitchcock | Cognitive Dysfunction, Cognitive Disorder, Epilepsy, Leukemia | 2 |
| Dartmouth-Hitchcock Clinics | Depression, Major Depressive Disorder, Obesity | 2 |
| Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center | Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis | 2 |
| Alice Peck Day Memorial Hospital | Suicide Attempt, Suicide Ideation | 1 |
| Children's Hospital at Dartmouth: Geisel School of Medicine | Child, Critical Illness, Hospital Acquired Pressure Ulcer | 1 |
| Cinical Study Site | Chronic Inflammatory Demyelinating Polyneuropathy | 1 |
| Clinical Trial Site | Lichen Planopilaris | 1 |
| Darthmouth-Hitchcock Medical Center | Alzheimer Disease | 1 |
| Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center | Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer | 1 |
| Dartmouth College | Anorexia Nervosa, Binge Eating Disorder, Bulimia Nervosa | 1 |
| Dartmouth Geisel School of Medicine | Spine Surgery | 1 |
| Dartmouth Hitchcock Cancer Center | Advanced Melanoma | 1 |
| Dartmouth Hitchcock Clinics Heater Road | Pyoderma Gangrenosum | 1 |
Active & Upcoming Studies in Lebanon (2026)
Recruiting trials in Lebanon grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (118 active studies)
- Implementation Intention Planning Guide for FIT Colon Cancer Screening · Dartmouth-Hitchcock Medical Center
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) · Phase 3 · Bristol-Myers Squibb
Neurology & pain (16 active studies)
- HOBSCOTCH-YOUTH and Young Adults · Dartmouth-Hitchcock Medical Center
- Influence of Lidocaine Infusion on Motor Evoked Potential Thresholds · Phase 4 · Dartmouth-Hitchcock Medical Center
Cardiovascular (8 active studies)
- Psychological Trauma, Post-Traumatic Stress Disorder, and Resilience in Adults With Congenital Heart Disease · Dartmouth-Hitchcock Medical Center
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention · Phase 4 · Duke University
Mental health & behavior (7 active studies)
- Digitally Enhanced Peer Doula Model for Perinatal Patients With Substance Use Disorder · Trustees of Dartmouth College
- Remote Evaluation and Alerting for Collaborative Health (REACH) in Depression · Dartmouth-Hitchcock Medical Center
Diabetes & metabolic (5 active studies)
- Phentermine's Impact on Treatment in Teens · Phase 2 · Russell McCulloh, MD
- Pilot Trial of the Move Healthier Group · Dartmouth-Hitchcock Medical Center
Pediatric (2 active studies)
- Participatory Approaches to Qualitative Research (PAQ): Comparing Two Approaches to Patient, Public and Clinician Involvement in Qualitative Research · Dartmouth-Hitchcock Medical Center
- Optimizing Tracheal Intubation Outcomes and Neonatal Safety · Children's Hospital of Philadelphia
Common conditions studied in Lebanon
- Acute Myeloid Leukemia (6 active studies)
- Breast Cancer (6 active studies)
- Epilepsy (6 active studies)
- Carcinoma, Non-Small-Cell Lung (5 active studies)
- Ulcerative Colitis (5 active studies)
- Non-Small Cell Lung Cancer (4 active studies)
Leading research sponsors in Lebanon
- Dartmouth-Hitchcock Medical Center
- National Cancer Institute (NCI)
- NRG Oncology
- Children's Oncology Group
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Lebanon?
There are approximately 252 recruiting clinical trials in Lebanon, New Hampshire listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Lebanon pay participants?
Most recruiting trials in Lebanon compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Lebanon?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Lebanon?
The most common conditions under active study in Lebanon include Acute Myeloid Leukemia (6), Breast Cancer (6), Epilepsy (6), Carcinoma, Non-Small-Cell Lung (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Lebanon?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Lebanon on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Lebanon?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Lebanon?
Recruiting research sites in Lebanon include Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Dartmouth Hitchcock Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Lebanon right now?
The largest active categories in Lebanon are Cancer & tumors (118), Neurology & pain (16), Cardiovascular (8). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.